Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued and United Therapeutics Corp (UTHR) is fairly valued.
Against our estimates of intrinsic value, UTHR trades at the wider discount: a margin of safety of +2%, against -110% for TEVA.
Values as of the 17 Nov 2026 close.
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.
Leak Score: free with an account
Discounting its cash flows at 8.2% (average of 3 methods) values the shares at $596.66; the price of $584.10 is 2% below that value, and 79% of that value comes from beyond year five.
Leak Score: free with an account
| Metric | TEVA | UTHR |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Price | $42.62 | $584.10 |
| Intrinsic value | $20.28 | $596.66 |
| Margin of safety | -110% | +2% |
| Market cap | $49.7B | $24.9B |
| Revenue growth, 5 years | 0.8% | 16.5% |
| Operating margin | 19.2% | 43.6% |
| Net margin | 2.9% | 38.6% |
| Return on equity | 6.7% | 19.1% |
| Debt to equity | 2.13 | 0.00 |
| P/E | 100.3x | 22.0x |
| Forward P/E | 13.7x | 19.6x |
| P/B | 6.2x | 3.9x |